1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors
ePostersLive by SciGen Technologies S.A. All rights reserved.
SOHO 2026 Annual Meeting
September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas
ABCL - 200
When Presentation Misleads: Diagnostic Challenges in Extranodal Diffuse Large B-Cell Lymphoma
Poster Presenter
Authors
Part of Topic
Aggressive B-Cell Lymphoma (ABCL)
Why does this matter?
•Atypical extranodal DLBCL frequently mimics benign or organ-specific diseases.
•Patients often undergo prolonged multidisciplinary investigations before lymphoma is suspected.
•Diagnostic delays may postpone appropriate treatment and adversely affect outcomes.
Study At a glance
•35 patients
•Single-Center
•2015-2025
•Retrospective study
Results
•PROLONGED DIAGNOSTIC JOURNEY
Complete diagnostic timelines available for 27/35 patients;
Complete diagnostic timelines available for 27/35 patients;
90 days median symptom-to-biopsy interval
42 days median biopsy-to-treatment interval
•ANATOMY MATTERED
Diagnostic complexity was greatest in anatomically misleading presentations, particularly craniofacial, ocular and joint-level bone disease
Diagnostic complexity was greatest in anatomically misleading presentations, particularly craniofacial, ocular and joint-level bone disease
•DISEASE FEATURES
Higher DCS was observed with Ki67 ≥80% and IPI ≥3
Higher DCS was observed with Ki67 ≥80% and IPI ≥3
•TREATMENT RESPONSE
78.9% ORR on interim PET-CT (n=19)
CR 42.1% · PR 36.8%
78.9% ORR on interim PET-CT (n=19)
CR 42.1% · PR 36.8%
Conclusions
•RECOGNIZE.
Atypical extranodal DLBCL often mimics benign or organ-specific disease, leading to complex, multidisciplinary diagnostic pathways.
•SUSPECT EARLYER
Early consideration of lymphoma and timely tissue biopsy may shorten the diagnostic journey.
IDENTIFY COMPLEXITY
The DCS may help identify patients with particularly complex diagnostic pathways and support earlier recognition.